Novo Nordisk Lowers 2025 Outlook, Names New CEO
Novo Nordisk cut its 2025 sales and profit forecast due to slower US Wegovy & Ozempic sales, hit by competition and compounded GLP-1s. Maziar Mike Doustdar is the new CEO.
/ 41 items
#Healthcare↓
Merck's Cost Cuts: Keytruda Patent & Gardasil Woes
Merck initiates $3B annual cost cuts by 2027 due to Keytruda's 2028 patent expiry & a 55% Q2 drop in Gardasil sales from China. Reinvesting for post-Keytruda growth.
PTC SEPHIENCE: A New PKU Treatment Approved
FDA-approved SEPHIENCE (sepiapterin), an oral drug, treats PKU in patients 1 month+. SEPHIENCE aims to be the future standard of care.
Apellis' EMPAVELI: First Treatment for Rare Kidney Diseases
FDA-approved EMPAVELI (pegcetacoplan) for C3G & IC-MPGN in patients 12+. Shows 68% proteinuria reduction, kidney function stabilization, and C3 deposit clearance. A transformational therapy for 5,000 US patients.
Celcuity's Gedatolisib Shows Unprecedented Breast Cancer Trial Results
Phase 3 VIKTORIA-1 trial shows gedatolisib triplet slashed disease progression risk by 76% in HR+/HER2- advanced breast cancer, with favorable safety.